These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38254099)

  • 1. A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer.
    Li X; Xiong F; Hu Z; Tao Q; Yang Y; Qiao X; Peng C; Jiang Y; Han M; Dong K; Hua Y; Zhang W; Xu M; Long W; Xiao Y; Wang D
    J Transl Med; 2024 Jan; 22(1):90. PubMed ID: 38254099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
    Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
    Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
    Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
    Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.
    Xiang K; Zhang M; Yang B; Liu X; Wang Y; Liu H; Song Y; Yuan Y; Zhang L; Wen T; Zhang GW
    Int Immunopharmacol; 2024 Jun; 134():112224. PubMed ID: 38723370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
    Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
    Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
    Hewitt LC; Inam IZ; Saito Y; Yoshikawa T; Quaas A; Hoelscher A; Bollschweiler E; Fazzi GE; Melotte V; Langley RE; Nankivell M; Cunningham D; Allum W; Hutchins GG; Grabsch HI
    Eur J Cancer; 2018 May; 94():104-114. PubMed ID: 29550565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherapy outcomes.
    Ying L; Hu Z; Lu Y; Tao Q; Xiong F; Shu Y; Yang Y; Qiao X; Peng C; Jiang Y; Han M; Xu M; Li X; Wang D
    Oncoimmunology; 2024; 13(1):2303195. PubMed ID: 38235318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
    Yang N; Wu Y; Jin M; Jia Z; Wang Y; Cao D; Qin L; Wang X; Zheng M; Cao X; Jiang J
    PeerJ; 2021; 9():e11481. PubMed ID: 34046266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma.
    Issin G; Sayar İ; Demir F; Bakkaloğlu İG; Gamsizkan M; Yildiz Z; Yilmaz I; Özmen SA; Çağatay DV; Zemheri IE; Demiriz M; Günal A
    J Environ Pathol Toxicol Oncol; 2023; 42(4):1-14. PubMed ID: 37522564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
    Pereira MA; Ramos MFKP; Cardili L; de Moraes RDR; Dias AR; Szor DJ; Zilberstein B; Alves VAF; de Mello ES; Ribeiro U
    J Gastrointest Surg; 2024 Feb; 28(2):151-157. PubMed ID: 38445936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
    Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
    Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
    Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
    Masetti M; Lindinger M; Lorenzen S
    Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.